Navigation Links
Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
Date:10/21/2008

Company Postpones Special Meeting of Shareholders until further notice

RICHMOND, Va., Oct. 21 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that on Thursday, October 16, 2008 NASDAQ issued a notice that:

-- Effective immediately, NASDAQ has suspended the enforcement of the rules

requiring a minimum $1.00 closing bid price.

-- Effective immediately, NASDAQ has also suspended the enforcement of the

rules requiring a minimum market value of publicly held shares (MVPHS).

-- NASDAQ will not take any action to delist any security for these

concerns during the suspension.

-- The suspension will remain in effect through Friday, January 16, 2009

and the original rules will be reinstated on Tuesday, January 20, 2009.

Prior to the suspension, Insmed had been given until December 15, 2008 to evidence a closing bid price of $1.00 or more for a minimum of 10 consecutive business days to remain listed on The NASDAQ Stock Market.

As a result of the rules suspension the Special Meeting of Shareholders, planned for November 24, 2008 to seek shareholder approval of a reverse split, should the Company need it, has been postponed until further notice.

Insmed will provide further information as it becomes available from NASDAQ.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, includ
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed to Seek Shareholder Approval for Reverse Split
2. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
3. Insmed to Present at Biosimilars 2008 Conference
4. Insmed to Present at BioPharm Asia 2008 Conference
5. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
6. Insmed CEO to Present at Drug Discovery & Development Conference
7. Insmed to Host Second Quarter 2008 Conference Call
8. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
9. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
10. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
11. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Technology to Find a Faster, More Accurate ... 1 ChemImage, ( www.chemimage.com ) today ... Breath, LLC ( www.nextbreath.net ), a leading ... ChemImage,s Raman Chemical Imaging for bioequivalence applications ...
... PETACH TIKVA, Israel, April 1 NexGen Biofuels,Ltd. ... a non-binding,Letter of Intent with World Venture Management ... ("WVM" ) and Mac Bioventures, Inc. The transaction,includes ... relating to its Real,Estate acquisitions and asset management ...
... 1 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), ... and oils in plant seeds, provides an ... insulin program. In December 2008, SemBioSys announced ... to license rights to SemBioSys, proprietary plant-produced ...
Cached Biology Technology:ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions 2ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions 3NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business 2SemBioSys provides update on insulin program 2SemBioSys provides update on insulin program 3
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Frontiers, one of the world,s fastest-growing Open Access publishers ... announces the launch of a new journal, Frontiers ... Health will publish high quality, rigorously peer-reviewed articles ... the entire research spectrum of Public Health. On ...
... Researchers at the UAB,s Institute of Environmental Science and ... have analysed the potential of different species of microalgae ... and the quantity of lipids per cell (essential for ... type of marine algae that has received little attention ...
... A Kansas State University research team has found ... nitrogen availability in many ecosystems has remained steady ... in the journal Nature . "People ... times because it,s a major pollutant," said Kendra ...
Cached Biology News:Frontiers announces launch of new open-access journal, Frontiers in Public Health 2Microalgae could be a profitable source of biodiesel 2Global nitrogen availability consistent for past 500 years, linked to carbon levels 2Global nitrogen availability consistent for past 500 years, linked to carbon levels 3
... Flight Mass Analyzer for superior sensitivity, mass accuracy, and resolving power., ... * Precursor ion selection range: 150 - 4000 m/z, * Resolution: ... internal reference, * Dynamic range: 4 orders of magnitude ... ...
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... NTI allows you to store and manage ... in a secure central relational database. Storing ... an invaluable resource for clone tracking and ... for immediate analysis. LabShare software integrates seamlessly ...
Biology Products: